ANXV development program

Retinal Vein Occlusion(RVO): Ongoing phase 2/Proof of Concept-study


How Annexin
A5 and ANXV work


ANXV treatment against retinal vein occlusion in the eye


About the drug candidate

The company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for acute treatment of patients with cardiovascular diseases, where vascular damage and inflammation are involved.

Research and development

Annexin’s drug candidate ANXV is a recombinant human Annexin A5. It is in development for intravenous administration in patients with acute vascular diseases, where ANXV is expected to improve the body’s own ability to protect and repair blood vessels.

Back to top